pioglitazone has been researched along with Coronary Stenosis in 5 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Coronary Stenosis: Narrowing or constriction of a coronary artery.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In all, 360 diabetic patients with coronary artery disease were treated with pioglitazone or glimepiride for 18 months in the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study." | 9.15 | Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression o ( Bayturan, O; Kupfer, S; Lavoie, A; Nesto, R; Nicholls, SJ; Nissen, SE; Perez, A; Tuzcu, EM; Uno, K; Wolski, K, 2011) |
| "In all, 360 diabetic patients with coronary artery disease were treated with pioglitazone or glimepiride for 18 months in the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study." | 5.15 | Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression o ( Bayturan, O; Kupfer, S; Lavoie, A; Nesto, R; Nicholls, SJ; Nissen, SE; Perez, A; Tuzcu, EM; Uno, K; Wolski, K, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nicholls, SJ | 1 |
| Tuzcu, EM | 1 |
| Wolski, K | 1 |
| Bayturan, O | 1 |
| Lavoie, A | 1 |
| Uno, K | 1 |
| Kupfer, S | 1 |
| Perez, A | 1 |
| Nesto, R | 1 |
| Nissen, SE | 1 |
| Patel, D | 1 |
| Walitt, B | 1 |
| Lindsay, J | 1 |
| Wilensky, RL | 1 |
| Kitahara, H | 1 |
| Kobayashi, Y | 1 |
| Iwata, Y | 1 |
| Fujimoto, Y | 1 |
| Komuro, I | 1 |
| Cho, L | 1 |
| Lewis, BE | 1 |
| Steen, LH | 1 |
| Leya, FS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind, Randomized, Comparator-Controlled Study In Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus Glimepiride on the Rate of Progression of Coronary Atherosclerotic Disease as Measured by Intravascular Ultr[NCT00225277] | Phase 3 | 547 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Due to low event rates, number of subjects experiencing any of the composite endpoint A cardiovascular events is being reported instead of time to first occurrence. Endpoint A conditions listed in Limitations and Caveats section. (NCT00225277)
Timeframe: Up to 72 weeks
| Intervention | Participants (Number) |
|---|---|
| Pioglitazone QD | 5 |
| Glimepiride QD | 6 |
Due to low event rates, number of subjects experiencing any of the composite endpoint B cardiovascular events is being reported instead of time to first occurrence. Endpoint B conditions listed in Limitations and Caveats section. (NCT00225277)
Timeframe: Up to 72 weeks
| Intervention | Participants (Number) |
|---|---|
| Pioglitazone QD | 40 |
| Glimepiride QD | 41 |
Due to low event rates, number of subjects experiencing any of the composite endpoint C cardiovascular events is being reported instead of time to first occurrence. Endpoint C conditions listed in Limitations and Caveats section. (NCT00225277)
Timeframe: Up to 72 weeks
| Intervention | participants (Number) |
|---|---|
| Pioglitazone QD | 11 |
| Glimepiride QD | 13 |
The nominal change in normalized total atheroma volume as measured by the average of plaque areas for all slices of anatomically comparable segments of the target coronary artery multiplied by the mean number of matched slices in the population. Assessment completed at the Week 72 visit or Final Visit if treatment was prematurely discontinued. (NCT00225277)
Timeframe: Baseline and Final Visit (up to 72 weeks)
| Intervention | Percent volume (Least Squares Mean) | |
|---|---|---|
| Baseline | Nominal Change from Baseline | |
| Glimepiride QD | 217.619 | -1.480 |
| Pioglitazone QD | 206.579 | -5.528 |
The nominal change from baseline in percent atheroma volume for all slices of anatomically comparable segments of the target coronary artery. Assessment completed at the Week 72 visit or Final Visit if treatment was prematurely discontinued. (NCT00225277)
Timeframe: Baseline and Final Visit (up to 72 weeks)
| Intervention | Percent volume (Least Squares Mean) | |
|---|---|---|
| Baseline | Nominal Change from Baseline | |
| Glimepiride QD | 40.016 | 0.725 |
| Pioglitazone QD | 40.592 | -0.161 |
The incidence of cardiovascular events and composite endpoints occurring within 30 days of last dose as adjudicated by the Clinical Endpoint Committee. Abbreviations: PCI: Percutaneous Coronary Intervention; CABG: Coronary Artery Bypass Graft; CHF: Congestive Heart Failure. (NCT00225277)
Timeframe: Up to 72 weeks
| Intervention | Number of Events (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nonfatal Myocardial Infarction | Nonfatal Stroke | Coronary Revascularization: PCI/CABG counted once | Coronary Revascularization: PCI | Coronary Revascularization: CABG | Carotid Endarterectomy/Stenting | Hospitalization for Unstable Angina | CHF Hospitalization: new/exacerbated counted once | Hospitalization for New CHF | Hospitalization for Exacerbated CHF | Noncardiovascular Mortality | Cardiovascular Mortality | Composite Endpoint A | Composite Endpoint B | Composite Endpoint C | |
| Glimepiride QD | 4 | 1 | 30 | 28 | 2 | 0 | 2 | 5 | 2 | 3 | 1 | 1 | 6 | 41 | 13 |
| Pioglitazone QD | 2 | 0 | 29 | 25 | 5 | 1 | 4 | 4 | 4 | 0 | 0 | 3 | 5 | 40 | 11 |
1 review available for pioglitazone and Coronary Stenosis
| Article | Year |
|---|---|
Role of pioglitazone in the prevention of restenosis and need for revascularization after bare-metal stent implantation: a meta-analysis.
Topics: Aged; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Coronary Angiography; Coronary Resten | 2011 |
2 trials available for pioglitazone and Coronary Stenosis
| Article | Year |
|---|---|
Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression o
Topics: Atherosclerosis; Cholesterol, HDL; Coronary Artery Disease; Coronary Stenosis; Diabetes Mellitus, Ty | 2011 |
Effect of pioglitazone on endothelial dysfunction after sirolimus-eluting stent implantation.
Topics: Acetylcholine; Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Stenosis; Corona | 2011 |
2 other studies available for pioglitazone and Coronary Stenosis
| Article | Year |
|---|---|
[Timely intervention with insulin sensitizer. Controlling cardiovascular risks].
Topics: Coronary Restenosis; Coronary Stenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Thera | 2003 |
Thiazolidinediones do not reduce target vessel revascularization in diabetic patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Cause of Death; Coronary Circulation; Coronary Stenosis; Diabe | 2005 |